New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints ...
Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors ...
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic ...
AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call ...
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and ...
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity ...
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease 1 Taken once daily with or without levodopa therapy, JUVMO offers patients a differentiated ...
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart, is ...
NORTH CHICAGO, Ill., Sept. 3, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced positive topline results from the Phase 3 CERVINO study 1 evaluating etentamig, an investigational BCMA x CD3 ...
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no ...
"The European Commission's approval of RINVOQ as the first and only systemic treatment for non-segmental vitiligo is an advancement for patients living with this chronic autoimmune disease," said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results